A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
about
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the prevention and treatment of postmenopausal osteoporosisTreating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?Prevention of hip fractures in long-term care: relevance of community-derived data.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Risedronate for the prevention of fractures in postmenopausal osteoporosis.Medical treatment of vertebral osteoporosisChanges in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisRisedronate for prevention and treatment of osteoporosis in postmenopausal women.The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis.The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis.Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings.Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.
P2860
Q24242674-D998D77C-FC76-4913-9E0E-3F51E8CF681EQ24245000-1E017EC9-4B6D-4AB9-8340-7D62C907FA4FQ33416959-159F70AA-8FEA-4712-A418-C4AFAE402A98Q33546626-E39C5ACB-F1D1-4C50-9E1B-624911B87297Q34300668-931C7EDF-8E48-45FD-8365-006543A25106Q34579629-E34653D1-847B-43C8-B4DF-C71A6C4A3AAFQ35299212-E27E6AB2-C69D-4A6C-9FCB-CC3BC63FD090Q35954529-2C2C2DC8-8C5D-4E1C-AFBC-0CC168CFEE99Q36044183-032F3D70-423A-4AA0-9262-E0B4AAD80CF5Q36045845-FC23698E-68EC-4BBC-8C4A-DB8AFBC2AEF5Q36082078-D7BA6280-2DDB-4F39-B0ED-061D849CCF68Q36317181-076BBA66-5D9D-4A97-A1FD-F91A8D00B24DQ41204558-5BA36C8C-CAB0-40B3-8392-C97EDF64817AQ48375169-96598BA6-A658-4247-81C1-8C2936E92307Q51832370-38B4D32F-0FE2-4798-8C8F-D14FC37BCA5A
P2860
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
A 2-year phase II study with 1 ...... n postmenopausal osteoporosis.
@en
type
label
A 2-year phase II study with 1 ...... n postmenopausal osteoporosis.
@en
prefLabel
A 2-year phase II study with 1 ...... n postmenopausal osteoporosis.
@en
P2093
P356
P1476
A 2-year phase II study with 1 ...... n postmenopausal osteoporosis.
@en
P2093
Christiansen C
Clemmesen B
Reginster JY
P2888
P304
P356
10.1007/PL00004152
P407
P577
1997-01-01T00:00:00Z
P6179
1032438702